Positive Health Online
Your Country
Research: REGEN and COLLEAGUES,
Listed in Issue 228
Abstract
REGEN and COLLEAGUES, (1)Department of Psychiatry, Clinical Neurobiology, Charité - Campus Benjamin Franklin, Berlin, Germany. (2)Department of Psychiatry, Clinical Neurobiology, Charité - Campus Benjamin Franklin, Berlin, Germany. Electronic address: julian.hellmann@charite.de investigated a hypothetical link between retinoic acid (RA) signalling and minocycline [a tetracycline antibiotic that fights bacteria in the body] for targeting prostate carcinoma (PCA).
Background
To elucidate a hypothetical link between retinoic acid (RA) signalling and minocycline [a tetracycline antibiotic that fights bacteria in the body] for targeting prostate carcinoma (PCA). RA signalling has been implicated in growth-inhibition of malignant PCA, and intracellular RA homeostasis has been investigated as a potential therapeutic target. Minocycline is a tetracycline antibiotic with pleiotropic actions in many tissues and reaches comparably high levels in human prostate tissue. Interestingly, minocycline exhibits the rare side effect of a pseudotumor cerebri, which is otherwise known to occur from vitamin A intoxication or in retinoid therapy. Therefore, we hypothesized minocycline to putatively interact with intracellular RA homeostasis in PCA.
Methodology
Using LN-CAP, DU-145, and PC-3 cell lines, effects of minocycline on microsomal RA metabolism and on cell growth were assessed in vitro.
Results
Minocycline was identified to potently inhibit cell growth, at concentrations within the range of tissue levels readily reached under standard therapeutic conditions. In vitro inhibition experiments revealed inhibition of RA breakdown, yet only at comparably high concentrations of minocycline. Using all trans-RA, RA metabolism inhibitor liarozole, and different retinoid receptor antagonists, the putative RA-dependent effects of minocycline were further evaluated and confirmed to be independent of RA signalling.
Conclusion
The authors’ findings add to the growing body of evidence for the many pleiotropic actions of minocycline. In view of the striking effects of minocycline on cell growth in PCA cell lines in vitro and its relatively safe side effect profile, the use of minocycline for targeting PCA should be timely clinically evaluated.
References
Regen F(1), Heuser I(1), Herzog I(1), Hellmann-Regen J(2). Striking growth-inhibitory effects of minocycline on human prostate cancer cell lines. Urology 83(2):509.e1-6. doi: 10.1016/j.urology.2013.10.029. Feb 2014. Epub 2013 Dec 19.